CN1261431C - 2h－1－苯并吡喃衍生物、它们的制备方法及其药物组合物 - Google Patents

2h－1－苯并吡喃衍生物、它们的制备方法及其药物组合物 Download PDF

Info

Publication number
CN1261431C
CN1261431C CNB02804066XA CN02804066A CN1261431C CN 1261431 C CN1261431 C CN 1261431C CN B02804066X A CNB02804066X A CN B02804066XA CN 02804066 A CN02804066 A CN 02804066A CN 1261431 C CN1261431 C CN 1261431C
Authority
CN
China
Prior art keywords
compound
alkyl
solution
phenyl
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB02804066XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1487934A (zh
Inventor
M·戴尔卡纳利
G·阿玛利
E·阿曼尼
M·希瓦利
E·加尔比亚蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01101521A external-priority patent/EP1229036B1/en
Priority claimed from EP01118682A external-priority patent/EP1281710A1/en
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Publication of CN1487934A publication Critical patent/CN1487934A/zh
Application granted granted Critical
Publication of CN1261431C publication Critical patent/CN1261431C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
CNB02804066XA 2001-01-24 2002-01-21 2h－1－苯并吡喃衍生物、它们的制备方法及其药物组合物 Expired - Fee Related CN1261431C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01101521.1 2001-01-24
EP01101521A EP1229036B1 (en) 2001-01-24 2001-01-24 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
EP01118682.2 2001-08-03
EP01118682A EP1281710A1 (en) 2001-08-03 2001-08-03 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof

Publications (2)

Publication Number Publication Date
CN1487934A CN1487934A (zh) 2004-04-07
CN1261431C true CN1261431C (zh) 2006-06-28

Family

ID=26076450

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB02804066XA Expired - Fee Related CN1261431C (zh) 2001-01-24 2002-01-21 2h－1－苯并吡喃衍生物、它们的制备方法及其药物组合物

Country Status (26)

Country Link
US (1) US6951883B2 (enExample)
EP (1) EP1355906B1 (enExample)
JP (1) JP4332349B2 (enExample)
CN (1) CN1261431C (enExample)
AT (1) ATE286894T1 (enExample)
AU (1) AU2002237282B2 (enExample)
BR (1) BR0207066A (enExample)
CA (1) CA2435775A1 (enExample)
CZ (1) CZ20032014A3 (enExample)
DE (1) DE60202590T2 (enExample)
DK (1) DK1355906T3 (enExample)
DZ (1) DZ3459A1 (enExample)
EA (1) EA006158B1 (enExample)
ES (1) ES2236485T3 (enExample)
HU (1) HUP0401018A3 (enExample)
IL (2) IL157065A0 (enExample)
MA (1) MA26982A1 (enExample)
MX (1) MXPA03006505A (enExample)
NO (1) NO327808B1 (enExample)
NZ (1) NZ527144A (enExample)
PL (1) PL365062A1 (enExample)
PT (1) PT1355906E (enExample)
SI (1) SI1355906T1 (enExample)
SK (1) SK287086B6 (enExample)
TN (1) TNSN03043A1 (enExample)
WO (1) WO2002059113A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4976649B2 (ja) * 2004-09-21 2012-07-18 マーシャル エドワーズ，インク． 化合物
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
WO2006032086A1 (en) * 2004-09-21 2006-03-30 Novogen Research Pty Ltd Chroman derivatives, medicaments and use in therapy
ATE532777T1 (de) * 2004-09-21 2011-11-15 Marshall Edwards Inc Substituierte chromanderivate, medikamente und anwendungen in der therapie
AU2005201855B2 (en) * 2004-09-21 2012-03-29 Marshall Edwards, Inc. Chroman derived compounds and formulations thereof for use in therapy
ES2377073T3 (es) * 2004-09-21 2012-03-22 Marshall Edwards, Inc. Derivados de cromano sustituidos, medicamentos y utilización en terapia
CN101444499B (zh) * 2007-11-26 2012-12-05 湘北威尔曼制药股份有限公司 一种化合物及其组合物的新用途
EP2635121B1 (en) 2010-11-01 2020-01-08 MEI Pharma, Inc. Isoflavonoid compounds and methods for the treatment of cancer
UA117249C2 (uk) 2013-06-19 2018-07-10 Серагон Фармасьютікалз, Інк. Модулятор рецептора естрогену та його застосування
HUE054998T2 (hu) 2015-02-02 2021-10-28 Mei Pharma Inc Kombinációs terápiák emlõrák kezelésében való alkalmazásra
MX394672B (es) * 2016-11-17 2025-03-21 Sanofi Sa Compuestos de n-(3-fluoropropil)-pirrolidina sustituidos novedosos, procesos para su preparacion y usos terapeuticos de los mismos.
EP3681495A4 (en) * 2017-09-15 2021-06-02 Nyrada Pty Limited TREATMENT OF EXCITOTOXICITY
CN112225716A (zh) * 2020-10-30 2021-01-15 陕西嘉禾生物科技股份有限公司 一种鹰嘴豆牙素a的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3374245A (en) * 1964-04-01 1968-03-19 Ciba Geigy Corp Unsaturated oxacycles
DE1518002C3 (de) * 1965-01-02 1975-01-23 Merck Patent Gmbh, 6100 Darmstadt Isoflavane und Isoflavene und Verfahren zu Ihrer Herstellung sowie diese enthaltende Arzneimittel
US5280040A (en) * 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
ZA979643B (en) 1996-10-28 1998-04-28 Novo Nordisk As Heterocyclic compounds, compositions and uses.
US5985306A (en) * 1996-10-28 1999-11-16 Novo Nordisk A/S (+)-enantiomers of cis-3,4-chroman derivatives useful in prevention or treatment of estrogen diseases or syndromes
DE69716292T2 (de) * 1996-12-13 2003-07-03 Chugai Seiyaku K.K., Tokio/Tokyo Benzopyranderivate
KR20000001793A (ko) * 1998-06-13 2000-01-15 이경하 신규한 벤조피란 또는 티오벤조피란 유도체
CA2356986A1 (en) * 1998-12-30 2000-07-06 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors

Also Published As

Publication number Publication date
PL365062A1 (en) 2004-12-27
HUP0401018A3 (en) 2007-05-29
IL157065A0 (en) 2004-02-08
SK9392003A3 (en) 2003-12-02
DE60202590D1 (de) 2005-02-17
EA200300727A1 (ru) 2004-02-26
DZ3459A1 (fr) 2002-08-01
HUP0401018A2 (hu) 2004-09-28
JP4332349B2 (ja) 2009-09-16
EP1355906A1 (en) 2003-10-29
US20040106595A1 (en) 2004-06-03
US6951883B2 (en) 2005-10-04
NO20033318L (no) 2003-09-24
NZ527144A (en) 2005-03-24
DK1355906T3 (da) 2005-05-30
TNSN03043A1 (en) 2005-12-23
EP1355906B1 (en) 2005-01-12
NO20033318D0 (no) 2003-07-23
MXPA03006505A (es) 2004-04-21
EA006158B1 (ru) 2005-10-27
AU2002237282B2 (en) 2007-02-15
MA26982A1 (fr) 2004-12-20
ATE286894T1 (de) 2005-01-15
HK1060558A1 (en) 2004-08-13
DE60202590T2 (de) 2005-12-29
WO2002059113A1 (en) 2002-08-01
SK287086B6 (sk) 2009-11-05
SI1355906T1 (en) 2005-06-30
CN1487934A (zh) 2004-04-07
CA2435775A1 (en) 2002-08-01
JP2004517151A (ja) 2004-06-10
CZ20032014A3 (cs) 2003-12-17
BR0207066A (pt) 2004-03-30
IL157065A (en) 2010-05-17
PT1355906E (pt) 2005-05-31
NO327808B1 (no) 2009-09-28
ES2236485T3 (es) 2005-07-16

Similar Documents

Publication Publication Date Title
CN1150166C (zh) Cb2受体拮抗剂化合物
CN1027068C (zh) α-取代的4-(喹啉-2-基-甲氧基)苯乙酸和酯的制备方法
CN1261431C (zh) 2h－1－苯并吡喃衍生物、它们的制备方法及其药物组合物
CN1538967A (zh) 杂环化合物和以其为有效成分的抗肿瘤药
CN1270585A (zh) 取代的1,2,3,4－四氢化萘衍生物
CN1168631A (zh) 治疗抗性肿瘤的方法
CN88102018A (zh) 1-苯基-3-萘氧基丙胺
CN1079219A (zh) 芳基乙酰胺
CN1154483C (zh) 胺化合物用于制备阻止肿瘤细胞增殖的药物
CN1173964C (zh) 新型苯并呋喃酮衍生物及其制备方法
CN1230432C (zh) 取代的苯基－哌嗪衍生物及其制备和用途
CN1244577C (zh) 4－苯基－1－哌嗪基、－哌啶基和－四氢吡啶基衍生物
CN1031262C (zh) 环取代的2-氨基-1，2，3，4-四氢化萘和3-氨基苯并二氢吡喃
CN1423637A (zh) 新的取代的三环化合物
CN1993343A (zh) 作为雌激素配体的四环化合物
CN1058494C (zh) 新的洋芫荽黄素化合物，其制备方法和含它们的药用组合物
CN1433410A (zh) 具有3－羟基色烯－4－酮结构的cdk抑制剂
CN1220660A (zh) 烷氧基氨基取代的芴酮以及它们作为蛋白激酶c抑制剂的用途
CN1662519A (zh) 新化合物及其作为甘氨酸转运抑制剂的用途
CN1437598A (zh) 新吲哚衍生物
CN1216856C (zh) 具有亚环烷基链的新环状化合物,其制备方法和含有它们的药物组合物
CN1703393A (zh) 螺环化合物、含有该化合物的药用组合物和该化合物的中间体
CN1303373A (zh) 用于治疗抑郁症的n－芳氧基乙基胺衍生物
CN1304403A (zh) 用于治疗抑郁症的n－芳氧基乙基－吲哚基－烷基胺(5－ht1a受体活化剂)
CN1052225C (zh) 石杉碱甲衍生物,其制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060628

Termination date: 20100221